Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.04 | 1.92 |
NAV | ₹19.37 | ₹38.82 |
Fund Started | 06 Oct 2020 | 25 Jun 2018 |
Fund Size | ₹153.72 Cr | ₹5044.63 Cr |
Exit Load | - | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 31.04% | 49.14% |
3 Year | 15.92% | 25.86% |
5 Year | - | 30.25% |
1 Year
3 Year
5 Year
Equity | 99.98% | 97.27% |
Cash | -0.12% | 2.73% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.13% |
Cipla Ltd. | 6.19% |
Max Healthcare Institute Ltd. | 5.85% |
Divi's Laboratories Ltd. | 5.67% |
Dr. Reddy's Laboratories Ltd. | 5.39% |
Apollo Hospitals Enterprise Ltd. | 5.28% |
Eli Lilly And Co | 4.99% |
Lupin Ltd. | 3.59% |
Johnson & Johnson Ltd. | 2.87% |
Novo Nordisk A/S - ADR | 2.65% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.77% |
Dr. Reddy's Laboratories Ltd. | 8.48% |
Cipla Ltd. | 7.94% |
Aurobindo Pharma Ltd. | 5.04% |
Gland Pharma Ltd. | 4.38% |
Lupin Ltd. | 4.29% |
Alkem Laboratories Ltd. | 4.16% |
Zydus Lifesciences Ltd. | 3.10% |
Apollo Hospitals Enterprise Ltd. | 2.93% |
Biocon Ltd. | 2.39% |
Name | Bhavesh Jain | Dharmesh Kakkad |
Start Date | 01 Oct 2021 | 23 Feb 2021 |
Name
Start Date
Description | The scheme seeks to invest in stocks comprising of the MSCI India Domestic & World Healthcare 45 Index with the objective to provide investment returns that, before expenses, closely corresponds to the returns equivalent to the index, subject to tracking errors. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 06 Oct 2020 | 25 Jun 2018 |
Description
Launch Date